LEADER 01745nam  2200421Ia 450 
001 9910695984403321
005 20070712163641.0
035   $a(CKB)5470000002373954
035   $a(OCoLC)154725758
035   $a(EXLCZ)995470000002373954
100   $a20070712d2007      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aPediatric drug research$b[electronic resource] $ethe study and labeling of drugs for pediatric use under the Best Pharmaceuticals for Children Act : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives /$fstatement of Marcia Crosse
210  1$a[Washington, D.C.] :$cU.S. Govt. Accountability Office,$d[2007]
215   $a14 pages $cdigital, PDF file
225 1 $aTestimony ;$vGAO-07-898 T
300   $aTitle from title screen (viewed on July 9, 2007).
300   $a"For release ... May 22, 2007."
300   $aPaper version available from: U.S. Govt. Accountability Office, 441 G St., NW, Rm. LM, Washington, D.C. 20548.
320   $aIncludes bibliographical references.
517   $aPediatric drug research 
606   $aPediatric pharmacology$zUnited States
606   $aDrugs$xResearch$zUnited States
615  0$aPediatric pharmacology
615  0$aDrugs$xResearch
700   $aCrosse$b Marcia$01380679
712 02$aUnited States.$bCongress.$bHouse.$bCommittee on Energy and Commerce.$bSubcommittee on Health.
712 02$aUnited States.$bGovernment Accountability Office.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910695984403321
996   $aPediatric drug research$93530961
997   $aUNINA